StockMarketWire.com - Ovoca Bio said it had recorded positive results from a trail of a treatment for hypoactive sexual desire disorder in premenopausal women.

Statistically significant top-line results were generated by a Phase 3 clinical trial of first candidate Libicore.

It was decided to stop the trial early after an independent data monitoring committee found the primary endpoint had reached its pre-specified criteria for superiority.

'We are excited with the trial result, which achieved clinical and statistical significance in the primary endpoint and key secondary endpoints using validated measurement tools,' chief executive Kirill Golovanov said.

'With approximately 1-in-10 adult women experiencing a distressing loss of libido and only a single FDA-approved therapy, we believe that Libicore has the potential to address a significant unmet medical need.'





Story provided by StockMarketWire.com